Rapport Therapeutics Inc Quick Ratio (RAPP) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Rapport Therapeutics Inc   (NASDAQ: RAPP)

Rapport Therapeutics Inc 's Quick Ratio

RAPP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 3.68 below Rapport Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Quick Ratio than Rapport Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 132 to 266.

Explain Quick Ratio?
How much Cash & cash equivalents RAPP´s has?
What are RAPP´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RAPP/financial-strength
https://api.csimarket.com/api/v1/companies/RAPP/fundamentals
https://api.csimarket.com/api/v1/companies/RAPP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
RAPP Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 41.81 %
Y / Y Cash & cash equivalent Change -85.43 %
Quick Ratio MRQ 3.68
RAPP's Total Ranking # 266
Seq. Current Liabilities Change -28.57 %
Seq. Cash & cash equivalent Change -82.86 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 97
Overall Market # 266


Quick Ratio Statistics
High Average Low
45.17 29.56 15.34
(Sep 30 2024)   (Jun 30 2026)




Financial Statements
Rapport Therapeutics Inc 's Current Liabilities $ 20 Millions Visit RAPP's Balance sheet
Rapport Therapeutics Inc 's Cash & cash equivalent $ 75 Millions Visit RAPP's Balance sheet
Source of RAPP's Sales Visit RAPP's Sales by Geography


Cumulative Rapport Therapeutics Inc 's Quick Ratio

RAPP's Quick Ratio for the trailling 12 Months

RAPP Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 93.19 %
Y / Y Cash & cash equivalent TTM Growth 8.36 %
Quick Ratio TTM 17.25
Total Ranking TTM # 3524
Seq. Current Liabilities TTM Growth 7.51 %
Seq. Cash & cash equivalent TTM Growth -22.87 %


  News about Rapport Therapeutics Inc Quick Ratio

Advancements in Seizure Biomarkers Insights from Rapport Therapeutics’ Phase 2a and Preclinical Trials

Rapport Therapeutics recently announced plans to present data at the American Epilepsy Society Annual Meeting, focusing on the outcomes of their Phase 2a trial, as well as preclinical and Phase 1 clinical data associated with seizure biomarkers. This article aims to outline the key findings and implications of these studies, which may provide significant advancements in the management and understanding of epilepsy. Epilepsy remains a complex neurological disorder affecting millions worldwide, characterized by recurrent seizures and significant comorbidity. Continuous efforts in research and development aim to identify reliable biomarkers for seizures, which can improve treatment protocols and patient management. Rapport Therapeutics has undertaken a rigorous approach to investigating such biomarkers, with recent announcements highlighting their upcoming presentations at the American Epilepsy Society Annual Meeting.


On the trailing twelve months basis Due to cut in Current Liabilities in the Q3 2026 to $20.30 millions, cumulative Quick Ratio decreased to 17.25 above the RAPP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Rapport Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2594 to 3524.

Explain Quick Ratio?
How much Cash & cash equivalents RAPP´s has?
What are RAPP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 421
Healthcare Sector # 857
Within the Market # 3524


trailing twelve months Quick Ratio Statistics
High Average Low
9.49 7.37 5.59
(Sep 30 2025)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Grace Therapeutics Inc  10.11 $ 21.311  Millions$ 2.107  Millions
Gri Bio Inc   9.94 $ 9.472  Millions$ 0.953  Millions
Nuvectis Pharma inc   9.91 $ 140.707  Millions$ 14.193  Millions
Renovorx Inc   9.76 $ 20.404  Millions$ 2.091  Millions
Aprea Therapeutics Inc   9.52 $ 37.846  Millions$ 3.975  Millions
Rezolute Inc   9.51 $ 89.999  Millions$ 9.463  Millions
Atrium Therapeutics Inc   9.42 $ 232.421  Millions$ 24.663  Millions
Cadrenal Therapeutics Inc  9.36 $ 5.162  Millions$ 0.551  Millions
Opus Genetics Inc   9.05 $ 88.974  Millions$ 9.832  Millions
Ibio inc   8.94 $ 76.654  Millions$ 8.574  Millions
Enveric Biosciences Inc   8.71 $ 5.613  Millions$ 0.644  Millions
Ideaya Biosciences Inc   8.70 $ 838.541  Millions$ 96.405  Millions
First Tracks Biotherapeutics Inc   8.60 $ 155.627  Millions$ 18.090  Millions
Aardvark Therapeutics Inc   8.58 $ 60.348  Millions$ 7.034  Millions
Pepgen Inc   8.48 $ 104.805  Millions$ 12.361  Millions
Medicinova Inc   8.47 $ 29.256  Millions$ 3.456  Millions
Polaryx Therapeutics Inc   8.45 $ 8.440  Millions$ 0.999  Millions
Ocular Therapeutix Inc   8.42 $ 530.612  Millions$ 63.017  Millions
Promis Neurosciences inc   8.26 $ 44.107  Millions$ 5.343  Millions
Evommune Inc   8.25 $ 169.033  Millions$ 20.483  Millions
Arvinas Inc   7.98 $ 558.400  Millions$ 70.000  Millions
Pliant Therapeutics Inc   7.90 $ 141.614  Millions$ 17.921  Millions
Wave Life Sciences Ltd   7.87 $ 431.012  Millions$ 54.760  Millions
Savara Inc   7.80 $ 129.649  Millions$ 16.630  Millions
Rigel Pharmaceuticals Inc  7.79 $ 224.456  Millions$ 28.806  Millions
Cytomx Therapeutics Inc   7.64 $ 347.980  Millions$ 45.532  Millions
Atea Pharmaceuticals Inc   7.64 $ 191.199  Millions$ 25.025  Millions
Cns Pharmaceuticals Inc   7.30 $ 17.212  Millions$ 2.359  Millions
Braveheart Bio, Inc.  7.27 $ 121.291  Millions$ 16.673  Millions
Viking Therapeutics Inc   7.17 $ 959.813  Millions$ 133.897  Millions

Date modified: 2026-11-05T10:09:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.